Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 10, 2023, serves as a notification to the U.S. Securities and Exchange Commission regarding the submission of the company's Annual Report on Form 20-F. The filing covers the audited financial statements for the fiscal year ended December 31, 2022.
Key Financial Metrics
The provided text does not contain specific financial data. It acts solely as a cover document announcing the availability of the full Annual Report. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing.
Material Changes
No material changes or comparative financial data are disclosed in this specific document. Investors are directed to the full Form 20-F for detailed performance analysis.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements. Management notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors referenced include those detailed in Item 3.D of the 2022 Form 20-F, Q4 2022 results, and potential impacts from the COVID-19 pandemic.
Investor Verification Checklist
- Verify the full audited financial statements in the Form 20-F available at www.gsk.com/corporatereporting or www.sec.gov.
- Review the "Risk factors" section (Item 3.D) in the 2022 Form 20-F for detailed disclosures on uncertainties.
- Confirm the date of the Annual General Meeting, with hard copies of the report expected around March 27, 2023.
- Check the Q4 2022 results for specific operational updates referenced in the risk statement.